Asia Movers To Watch: Astellas, Kyowa Hakko, CMIC, CFDA
Executive Summary
February brings new executives at Japan's Astellas, Kyowa Hakko Bio and CMIC. Meanwhile, China FDA deputy commissioner has departed to become the head of an influential academic organization.
You may also be interested in...
Stock Scan February 2018: Wet But Above Water
The market slump at the beginning of February affected virtually all of the stocks of the top 50 pharmaceutical companies. But unpredicted clinical successes or surprisingly good financials still kept a few companies above water.
Homegrown China Oral Antiviral Shows Early Promise
Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.
China Takes A Bigger Role In The World Pharma Stage
2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.